💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ipratropium

CHEMBL1621597 Phase 4 승인됨 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
332.5 g/mol
LogP
2.6
Phase
4

This anticholinergic bronchodilator is used to relieve bronchospasm in COPD and asthma by blocking muscarinic receptors in the airways, preventing the smooth muscle constriction caused by the vagal nerve. It helps open the airways and reduce mucus secretion. It is available in inhaled forms for maintenance therapy and is often combined with short-acting beta-agonists.

분자량

332.5000 g/mol

LogP

2.60

TPSA

46.50 Ų

리핀스키 5의 법칙

통과

치료 영역

Non-Small Cell Lung Cancer Asthma Chronic Obstructive Pulmonary Disease Parkinson's Disease Obesity Hypertension Heart Failure

작용 기전

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2

                

                

                
                

                    
InChI

                    
InChI=1S/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1/t16-,17+,18+,19?,21?

                

                

                

                    
                    

                        
Molecular Formula

                        
C20H30NO3+

                    

                    
                    

                        
HBD / HBA

                        
1 / 3

                    

                    
                    

                        
회전 가능 결합

                        
6

                    

                    
                    
                    

                        
무거운 원자

                        
24

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
This anticholinergic bronchodilator is used to relieve bronchospasm in COPD and asthma by blocking muscarinic receptors in the airways, preventing the smooth muscle constriction caused by the vagal nerve. It helps open the airways and reduce mucus secretion. It is available in inhaled forms for maintenance therapy and is often combined with short-acting beta-agonists.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Ipratropium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1621597.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 657309.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.